• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ADRX
Share

ADARx Pharmaceuticals, Inc. Stocks

$ 14.91Last Updated 12.11.2026

Issuer Rating

Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

$ 1.49B

$ 14.91
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

25.09.2026 15:00

ADARx IPO: Late-stage developer of gene therapies goes public

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.11.2026 19:49

Cybersecurity stocks failed to sustain their gains amid a Microsoft outage

13.11.2026 19:08

Betting on Automation and Leadership: Why Freedom Expects Anthropic's Stock to Rise 31%

13.11.2026 18:55

The Litmus Test of the AI Market: How to Assess the Prospects of NeoClouds?

13.11.2026 18:32

The rotation away from Nvidia in the chip sector has broadened. The market has turned to less speculative plays.

13.11.2026 17:55

Bloomberg learned of Nvidia's problems with its AI project support program before Huang stepped down

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026